All trades / SKYE
65Open-market trades
+7.37%Avg 90d after buys
+44.7%Avg 90d after sales
+78.8%Avg 180d after buys
Price and insider prints
SKYE adjusted close▲ buy▼ sale
Trades
| Date | Form 4 | Ticker | Insider | Side | Shares | Value | 90d | 180d |
|---|---|---|---|---|---|---|---|---|
| 9/16/2026 | SKYESkye Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | 5AM CO-INVESTORS II LP · 5AM Partners II, LLC · 5AM Partners VII, LLC · 5AM Ventures II LP · 5AM Ventures VII, L.P. · DIEKMAN JOHN D · PARMAR KUSH · ROCKLAGE SCOTT M10% owner | SELL | 1,285 | $2.5K | +11.2%hist | +5.59%hist | |
| 9/16/2026 | SKYESkye Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | 5AM CO-INVESTORS II LP · 5AM Partners II, LLC · 5AM Partners VII, LLC · 5AM Ventures II LP · 5AM Ventures VII, L.P. · DIEKMAN JOHN D · PARMAR KUSH · ROCKLAGE SCOTT M10% owner | SELL | 32,607 | $62.3K | +11.2%hist | +5.59%hist | |
| 9/16/2026 | SKYESkye Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | Schwab Andrew J.10% owner and DirectorAndrew J. Schwab has served on our Board of Directors since the closing of our merger with Bird Rock Bio in August 2023 . Mr. Schwab is a Founding Partner and Managing Member of 5AM Venture Management, LLC, a venture capital firm focused on next generation life science investments founded in 2002. At 5AM, Mr. Schwab has led the firm’s investments in and currently also serves on the Board of Directors of Camp4 Therapeutics Corporation since March 2021, Fellow Health, Inc. since August 2022, Radionetics Oncology, Inc. since September 2021, Rarecyte, Inc. since December 2019, Scientist.com since November 2019, and TMRW Holdings, LLC since December 2019. Mr. Schwab previously served on the Board of Directors of… | SELL | 32,607 | $62.3K | +17.0%hist | +13.2%hist | |
| 9/16/2026 | SKYESkye Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | Schwab Andrew J.10% owner and DirectorAndrew J. Schwab has served on our Board of Directors since the closing of our merger with Bird Rock Bio in August 2023 . Mr. Schwab is a Founding Partner and Managing Member of 5AM Venture Management, LLC, a venture capital firm focused on next generation life science investments founded in 2002. At 5AM, Mr. Schwab has led the firm’s investments in and currently also serves on the Board of Directors of Camp4 Therapeutics Corporation since March 2021, Fellow Health, Inc. since August 2022, Radionetics Oncology, Inc. since September 2021, Rarecyte, Inc. since December 2019, Scientist.com since November 2019, and TMRW Holdings, LLC since December 2019. Mr. Schwab previously served on the Board of Directors of… | SELL | 1,285 | $2.5K | +17.0%hist | +13.2%hist | |
| 8/20/2026 | SKYESkye Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | 5AM CO-INVESTORS II LP · 5AM Partners II, LLC · 5AM Partners VII, LLC · 5AM Ventures II LP · 5AM Ventures VII, L.P. · DIEKMAN JOHN D · PARMAR KUSH · ROCKLAGE SCOTT M10% owner | SELL | 6,495 | $2.1K | +11.2%hist | +5.59%hist | |
| 8/20/2026 | SKYESkye Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | 5AM CO-INVESTORS II LP · 5AM Partners II, LLC · 5AM Partners VII, LLC · 5AM Ventures II LP · 5AM Ventures VII, L.P. · DIEKMAN JOHN D · PARMAR KUSH · ROCKLAGE SCOTT M10% owner | SELL | 46 | $14.72 | +11.2%hist | +5.59%hist | |
| 8/20/2026 | SKYESkye Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | 5AM CO-INVESTORS II LP · 5AM Partners II, LLC · 5AM Partners VII, LLC · 5AM Ventures II LP · 5AM Ventures VII, L.P. · DIEKMAN JOHN D · PARMAR KUSH · ROCKLAGE SCOTT M10% owner | SELL | 1,159 | $370.88 | +11.2%hist | +5.59%hist | |
| 8/20/2026 | SKYESkye Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | Schwab Andrew J.10% owner and DirectorAndrew J. Schwab has served on our Board of Directors since the closing of our merger with Bird Rock Bio in August 2023 . Mr. Schwab is a Founding Partner and Managing Member of 5AM Venture Management, LLC, a venture capital firm focused on next generation life science investments founded in 2002. At 5AM, Mr. Schwab has led the firm’s investments in and currently also serves on the Board of Directors of Camp4 Therapeutics Corporation since March 2021, Fellow Health, Inc. since August 2022, Radionetics Oncology, Inc. since September 2021, Rarecyte, Inc. since December 2019, Scientist.com since November 2019, and TMRW Holdings, LLC since December 2019. Mr. Schwab previously served on the Board of Directors of… | SELL | 1,159 | $370.88 | +17.0%hist | +13.2%hist | |
| 8/20/2026 | SKYESkye Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | Schwab Andrew J.10% owner and DirectorAndrew J. Schwab has served on our Board of Directors since the closing of our merger with Bird Rock Bio in August 2023 . Mr. Schwab is a Founding Partner and Managing Member of 5AM Venture Management, LLC, a venture capital firm focused on next generation life science investments founded in 2002. At 5AM, Mr. Schwab has led the firm’s investments in and currently also serves on the Board of Directors of Camp4 Therapeutics Corporation since March 2021, Fellow Health, Inc. since August 2022, Radionetics Oncology, Inc. since September 2021, Rarecyte, Inc. since December 2019, Scientist.com since November 2019, and TMRW Holdings, LLC since December 2019. Mr. Schwab previously served on the Board of Directors of… | SELL | 46 | $14.72 | +17.0%hist | +13.2%hist | |
| 8/20/2026 | SKYESkye Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | Schwab Andrew J.10% owner and DirectorAndrew J. Schwab has served on our Board of Directors since the closing of our merger with Bird Rock Bio in August 2023 . Mr. Schwab is a Founding Partner and Managing Member of 5AM Venture Management, LLC, a venture capital firm focused on next generation life science investments founded in 2002. At 5AM, Mr. Schwab has led the firm’s investments in and currently also serves on the Board of Directors of Camp4 Therapeutics Corporation since March 2021, Fellow Health, Inc. since August 2022, Radionetics Oncology, Inc. since September 2021, Rarecyte, Inc. since December 2019, Scientist.com since November 2019, and TMRW Holdings, LLC since December 2019. Mr. Schwab previously served on the Board of Directors of… | SELL | 6,495 | $2.1K | +17.0%hist | +13.2%hist | |
| 8/19/2026 | SKYESkye Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | 5AM CO-INVESTORS II LP · 5AM Partners II, LLC · 5AM Partners VII, LLC · 5AM Ventures II LP · 5AM Ventures VII, L.P. · DIEKMAN JOHN D · PARMAR KUSH · ROCKLAGE SCOTT M10% owner | SELL | 57,476 | $20.1K | +11.2%hist | +5.59%hist | |
| 8/19/2026 | SKYESkye Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | 5AM CO-INVESTORS II LP · 5AM Partners II, LLC · 5AM Partners VII, LLC · 5AM Ventures II LP · 5AM Ventures VII, L.P. · DIEKMAN JOHN D · PARMAR KUSH · ROCKLAGE SCOTT M10% owner | SELL | 409 | $143.15 | +11.2%hist | +5.59%hist | |
| 8/19/2026 | SKYESkye Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | 5AM CO-INVESTORS II LP · 5AM Partners II, LLC · 5AM Partners VII, LLC · 5AM Ventures II LP · 5AM Ventures VII, L.P. · DIEKMAN JOHN D · PARMAR KUSH · ROCKLAGE SCOTT M10% owner | SELL | 10,255 | $3.6K | +11.2%hist | +5.59%hist | |
| 8/19/2026 | SKYESkye Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | Schwab Andrew J.10% owner and DirectorAndrew J. Schwab has served on our Board of Directors since the closing of our merger with Bird Rock Bio in August 2023 . Mr. Schwab is a Founding Partner and Managing Member of 5AM Venture Management, LLC, a venture capital firm focused on next generation life science investments founded in 2002. At 5AM, Mr. Schwab has led the firm’s investments in and currently also serves on the Board of Directors of Camp4 Therapeutics Corporation since March 2021, Fellow Health, Inc. since August 2022, Radionetics Oncology, Inc. since September 2021, Rarecyte, Inc. since December 2019, Scientist.com since November 2019, and TMRW Holdings, LLC since December 2019. Mr. Schwab previously served on the Board of Directors of… | SELL | 10,255 | $3.6K | +17.0%hist | +13.2%hist | |
| 8/19/2026 | SKYESkye Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | Schwab Andrew J.10% owner and DirectorAndrew J. Schwab has served on our Board of Directors since the closing of our merger with Bird Rock Bio in August 2023 . Mr. Schwab is a Founding Partner and Managing Member of 5AM Venture Management, LLC, a venture capital firm focused on next generation life science investments founded in 2002. At 5AM, Mr. Schwab has led the firm’s investments in and currently also serves on the Board of Directors of Camp4 Therapeutics Corporation since March 2021, Fellow Health, Inc. since August 2022, Radionetics Oncology, Inc. since September 2021, Rarecyte, Inc. since December 2019, Scientist.com since November 2019, and TMRW Holdings, LLC since December 2019. Mr. Schwab previously served on the Board of Directors of… | SELL | 409 | $143.15 | +17.0%hist | +13.2%hist | |
| 8/19/2026 | SKYESkye Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | Schwab Andrew J.10% owner and DirectorAndrew J. Schwab has served on our Board of Directors since the closing of our merger with Bird Rock Bio in August 2023 . Mr. Schwab is a Founding Partner and Managing Member of 5AM Venture Management, LLC, a venture capital firm focused on next generation life science investments founded in 2002. At 5AM, Mr. Schwab has led the firm’s investments in and currently also serves on the Board of Directors of Camp4 Therapeutics Corporation since March 2021, Fellow Health, Inc. since August 2022, Radionetics Oncology, Inc. since September 2021, Rarecyte, Inc. since December 2019, Scientist.com since November 2019, and TMRW Holdings, LLC since December 2019. Mr. Schwab previously served on the Board of Directors of… | SELL | 57,476 | $20.1K | +17.0%hist | +13.2%hist | |
| 8/18/2026 | SKYESkye Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | 5AM CO-INVESTORS II LP · 5AM Partners II, LLC · 5AM Partners VII, LLC · 5AM Ventures II LP · 5AM Ventures VII, L.P. · DIEKMAN JOHN D · PARMAR KUSH · ROCKLAGE SCOTT M10% owner | SELL | 253,080 | $96.2K | +11.2%hist | +5.59%hist | |
| 8/18/2026 | SKYESkye Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | 5AM CO-INVESTORS II LP · 5AM Partners II, LLC · 5AM Partners VII, LLC · 5AM Ventures II LP · 5AM Ventures VII, L.P. · DIEKMAN JOHN D · PARMAR KUSH · ROCKLAGE SCOTT M10% owner | SELL | 1,830 | $695.40 | +11.2%hist | +5.59%hist | |
| 8/18/2026 | SKYESkye Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | 5AM CO-INVESTORS II LP · 5AM Partners II, LLC · 5AM Partners VII, LLC · 5AM Ventures II LP · 5AM Ventures VII, L.P. · DIEKMAN JOHN D · PARMAR KUSH · ROCKLAGE SCOTT M10% owner | SELL | 45,090 | $17.1K | +11.2%hist | +5.59%hist | |
| 8/18/2026 | SKYESkye Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | Schwab Andrew J.10% owner and DirectorAndrew J. Schwab has served on our Board of Directors since the closing of our merger with Bird Rock Bio in August 2023 . Mr. Schwab is a Founding Partner and Managing Member of 5AM Venture Management, LLC, a venture capital firm focused on next generation life science investments founded in 2002. At 5AM, Mr. Schwab has led the firm’s investments in and currently also serves on the Board of Directors of Camp4 Therapeutics Corporation since March 2021, Fellow Health, Inc. since August 2022, Radionetics Oncology, Inc. since September 2021, Rarecyte, Inc. since December 2019, Scientist.com since November 2019, and TMRW Holdings, LLC since December 2019. Mr. Schwab previously served on the Board of Directors of… | SELL | 45,090 | $17.1K | +17.0%hist | +13.2%hist | |
| 8/18/2026 | SKYESkye Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | Schwab Andrew J.10% owner and DirectorAndrew J. Schwab has served on our Board of Directors since the closing of our merger with Bird Rock Bio in August 2023 . Mr. Schwab is a Founding Partner and Managing Member of 5AM Venture Management, LLC, a venture capital firm focused on next generation life science investments founded in 2002. At 5AM, Mr. Schwab has led the firm’s investments in and currently also serves on the Board of Directors of Camp4 Therapeutics Corporation since March 2021, Fellow Health, Inc. since August 2022, Radionetics Oncology, Inc. since September 2021, Rarecyte, Inc. since December 2019, Scientist.com since November 2019, and TMRW Holdings, LLC since December 2019. Mr. Schwab previously served on the Board of Directors of… | SELL | 1,830 | $695.40 | +17.0%hist | +13.2%hist | |
| 8/18/2026 | SKYESkye Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | Schwab Andrew J.10% owner and DirectorAndrew J. Schwab has served on our Board of Directors since the closing of our merger with Bird Rock Bio in August 2023 . Mr. Schwab is a Founding Partner and Managing Member of 5AM Venture Management, LLC, a venture capital firm focused on next generation life science investments founded in 2002. At 5AM, Mr. Schwab has led the firm’s investments in and currently also serves on the Board of Directors of Camp4 Therapeutics Corporation since March 2021, Fellow Health, Inc. since August 2022, Radionetics Oncology, Inc. since September 2021, Rarecyte, Inc. since December 2019, Scientist.com since November 2019, and TMRW Holdings, LLC since December 2019. Mr. Schwab previously served on the Board of Directors of… | SELL | 253,080 | $96.2K | +17.0%hist | +13.2%hist | |
| 8/22/2025 | SKYESkye Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | Schwab Andrew J.10% owner and DirectorAndrew J. Schwab has served on our Board of Directors since the closing of our merger with Bird Rock Bio in August 2023 . Mr. Schwab is a Founding Partner and Managing Member of 5AM Venture Management, LLC, a venture capital firm focused on next generation life science investments founded in 2002. At 5AM, Mr. Schwab has led the firm’s investments in and currently also serves on the Board of Directors of Camp4 Therapeutics Corporation since March 2021, Fellow Health, Inc. since August 2022, Radionetics Oncology, Inc. since September 2021, Rarecyte, Inc. since December 2019, Scientist.com since November 2019, and TMRW Holdings, LLC since December 2019. Mr. Schwab previously served on the Board of Directors of… | SELL | 163,979 | $560.8K | +62.0% | +76.2% | |
| 8/22/2025 | SKYESkye Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | Schwab Andrew J.10% owner and DirectorAndrew J. Schwab has served on our Board of Directors since the closing of our merger with Bird Rock Bio in August 2023 . Mr. Schwab is a Founding Partner and Managing Member of 5AM Venture Management, LLC, a venture capital firm focused on next generation life science investments founded in 2002. At 5AM, Mr. Schwab has led the firm’s investments in and currently also serves on the Board of Directors of Camp4 Therapeutics Corporation since March 2021, Fellow Health, Inc. since August 2022, Radionetics Oncology, Inc. since September 2021, Rarecyte, Inc. since December 2019, Scientist.com since November 2019, and TMRW Holdings, LLC since December 2019. Mr. Schwab previously served on the Board of Directors of… | SELL | 6,470 | $22.1K | +62.0% | +76.2% | |
| 8/22/2025 | SKYESkye Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | 5AM CO-INVESTORS II LP · 5AM Partners II, LLC · 5AM Partners VII, LLC · 5AM Ventures II LP · 5AM Ventures VII, L.P. · DIEKMAN JOHN D · PARMAR KUSH · ROCKLAGE SCOTT M10% owner | SELL | 6,470 | $22.1K | +62.0% | +76.2% | |
| 8/22/2025 | SKYESkye Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | 5AM CO-INVESTORS II LP · 5AM Partners II, LLC · 5AM Partners VII, LLC · 5AM Ventures II LP · 5AM Ventures VII, L.P. · DIEKMAN JOHN D · PARMAR KUSH · ROCKLAGE SCOTT M10% owner | SELL | 163,979 | $560.8K | +62.0% | +76.2% | |
| 8/21/2025 | SKYESkye Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | Schwab Andrew J.10% owner and DirectorAndrew J. Schwab has served on our Board of Directors since the closing of our merger with Bird Rock Bio in August 2023 . Mr. Schwab is a Founding Partner and Managing Member of 5AM Venture Management, LLC, a venture capital firm focused on next generation life science investments founded in 2002. At 5AM, Mr. Schwab has led the firm’s investments in and currently also serves on the Board of Directors of Camp4 Therapeutics Corporation since March 2021, Fellow Health, Inc. since August 2022, Radionetics Oncology, Inc. since September 2021, Rarecyte, Inc. since December 2019, Scientist.com since November 2019, and TMRW Holdings, LLC since December 2019. Mr. Schwab previously served on the Board of Directors of… | SELL | 2,314 | $8.3K | +63.1% | +79.2% | |
| 8/21/2025 | SKYESkye Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | Schwab Andrew J.10% owner and DirectorAndrew J. Schwab has served on our Board of Directors since the closing of our merger with Bird Rock Bio in August 2023 . Mr. Schwab is a Founding Partner and Managing Member of 5AM Venture Management, LLC, a venture capital firm focused on next generation life science investments founded in 2002. At 5AM, Mr. Schwab has led the firm’s investments in and currently also serves on the Board of Directors of Camp4 Therapeutics Corporation since March 2021, Fellow Health, Inc. since August 2022, Radionetics Oncology, Inc. since September 2021, Rarecyte, Inc. since December 2019, Scientist.com since November 2019, and TMRW Holdings, LLC since December 2019. Mr. Schwab previously served on the Board of Directors of… | SELL | 58,642 | $209.4K | +63.1% | +79.2% | |
| 8/21/2025 | SKYESkye Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | 5AM CO-INVESTORS II LP · 5AM Partners II, LLC · 5AM Partners VII, LLC · 5AM Ventures II LP · 5AM Ventures VII, L.P. · DIEKMAN JOHN D · PARMAR KUSH · ROCKLAGE SCOTT M10% owner | SELL | 58,642 | $209.4K | +63.1% | +79.2% | |
| 8/21/2025 | SKYESkye Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | 5AM CO-INVESTORS II LP · 5AM Partners II, LLC · 5AM Partners VII, LLC · 5AM Ventures II LP · 5AM Ventures VII, L.P. · DIEKMAN JOHN D · PARMAR KUSH · ROCKLAGE SCOTT M10% owner | SELL | 2,314 | $8.3K | +63.1% | +79.2% | |
| 11/18/2024 | SKYESkye Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | ARSENAULT KAITLYNChief Financial Officer | SELL | 43,026 | $214.7K | +31.8% | +52.9% | |
| 11/18/2024 | SKYESkye Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | Grayson Paul A.DirectorPaul Grayson has served on our Board of Directors since the closing of our merger with Bird Rock Bio, Inc. (“Bird Rock Bio”) in August 2023. Mr. Grayson was appointed as Chairman of the Board of Directors in October 2024. Mr. Grayson has served as President and Chief Executive Officer and director of Radionetics Oncology, Inc., a clinical stage biotechnology company focused on novel radiopharmaceutical products, since November 2023. From July 2020 to November 2023, Mr. Grayson served as President and Chief Executive Officer of Tentarix Biotherapeutics Inc., a biotechnology company. Mr .Grayson served as President and Chief Executive Officer of Bird Rock Bio, a clinical stage biopharmaceutical company, from… | SELL | 86,244 | $430.4K | +31.8% | +52.9% | |
| 11/18/2024 | SKYESkye Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | ARSENAULT KAITLYNChief Financial Officer | SELL | 43,206 | $215.6K | +31.8% | +52.9% | |
| 11/18/2024 | SKYESkye Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | DHILLON PUNITChief Executive Officer | SELL | 82,546 | $411.9K | +31.8% | +52.9% | |
| 11/18/2024 | SKYESkye Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | Diep Tuan TuChief Development Officer | SELL | 19,489 | $97.3K | +31.8% | +52.9% | |
| 11/15/2024 | SKYESkye Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | ARSENAULT KAITLYNChief Financial Officer | SELL | 190 | $1.1K | +38.2% | +61.6% | |
| 11/15/2024 | SKYESkye Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | Grayson Paul A.DirectorPaul Grayson has served on our Board of Directors since the closing of our merger with Bird Rock Bio, Inc. (“Bird Rock Bio”) in August 2023. Mr. Grayson was appointed as Chairman of the Board of Directors in October 2024. Mr. Grayson has served as President and Chief Executive Officer and director of Radionetics Oncology, Inc., a clinical stage biotechnology company focused on novel radiopharmaceutical products, since November 2023. From July 2020 to November 2023, Mr. Grayson served as President and Chief Executive Officer of Tentarix Biotherapeutics Inc., a biotechnology company. Mr .Grayson served as President and Chief Executive Officer of Bird Rock Bio, a clinical stage biopharmaceutical company, from… | SELL | 307 | $1.7K | +38.2% | +61.6% | |
| 11/15/2024 | SKYESkye Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | ARSENAULT KAITLYNChief Financial Officer | SELL | 190 | $1.1K | +38.2% | +61.6% | |
| 11/15/2024 | SKYESkye Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | DHILLON PUNITChief Executive Officer | SELL | 364 | $2.0K | +38.2% | +61.6% | |
| 11/15/2024 | SKYESkye Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | Diep Tuan TuChief Development Officer | SELL | 85 | $471.75 | +38.2% | +61.6% | |
| 9/13/2024 | SKYESkye Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | 5AM CO-INVESTORS II LP · 5AM Partners II, LLC · 5AM Partners VII, LLC · 5AM Ventures II LP · 5AM Ventures VII, L.P. · DIEKMAN JOHN D · PARMAR KUSH · ROCKLAGE SCOTT M10% owner | SELL | 79 | $478.74 | +44.2% | +53.7% | |
| 9/13/2024 | SKYESkye Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | 5AM CO-INVESTORS II LP · 5AM Partners II, LLC · 5AM Partners VII, LLC · 5AM Ventures II LP · 5AM Ventures VII, L.P. · DIEKMAN JOHN D · PARMAR KUSH · ROCKLAGE SCOTT M10% owner | SELL | 2,000 | $12.1K | +44.2% | +53.7% | |
| 9/13/2024 | SKYESkye Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | 5AM CO-INVESTORS II LP · 5AM Partners II, LLC · 5AM Partners VII, LLC · 5AM Ventures II LP · 5AM Ventures VII, L.P. · DIEKMAN JOHN D · PARMAR KUSH · ROCKLAGE SCOTT M10% owner | SELL | 11,758 | $71.3K | +44.2% | +53.7% | |
| 9/13/2024 | SKYESkye Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | Schwab Andrew J.10% owner and DirectorAndrew J. Schwab has served on our Board of Directors since the closing of our merger with Bird Rock Bio in August 2023 . Mr. Schwab is a Founding Partner and Managing Member of 5AM Venture Management, LLC, a venture capital firm focused on next generation life science investments founded in 2002. At 5AM, Mr. Schwab has led the firm’s investments in and currently also serves on the Board of Directors of Camp4 Therapeutics Corporation since March 2021, Fellow Health, Inc. since August 2022, Radionetics Oncology, Inc. since September 2021, Rarecyte, Inc. since December 2019, Scientist.com since November 2019, and TMRW Holdings, LLC since December 2019. Mr. Schwab previously served on the Board of Directors of… | SELL | 79 | $478.74 | +44.2% | +53.7% | |
| 9/13/2024 | SKYESkye Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | Schwab Andrew J.10% owner and DirectorAndrew J. Schwab has served on our Board of Directors since the closing of our merger with Bird Rock Bio in August 2023 . Mr. Schwab is a Founding Partner and Managing Member of 5AM Venture Management, LLC, a venture capital firm focused on next generation life science investments founded in 2002. At 5AM, Mr. Schwab has led the firm’s investments in and currently also serves on the Board of Directors of Camp4 Therapeutics Corporation since March 2021, Fellow Health, Inc. since August 2022, Radionetics Oncology, Inc. since September 2021, Rarecyte, Inc. since December 2019, Scientist.com since November 2019, and TMRW Holdings, LLC since December 2019. Mr. Schwab previously served on the Board of Directors of… | SELL | 2,000 | $12.1K | +44.2% | +53.7% | |
| 9/13/2024 | SKYESkye Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | Schwab Andrew J.10% owner and DirectorAndrew J. Schwab has served on our Board of Directors since the closing of our merger with Bird Rock Bio in August 2023 . Mr. Schwab is a Founding Partner and Managing Member of 5AM Venture Management, LLC, a venture capital firm focused on next generation life science investments founded in 2002. At 5AM, Mr. Schwab has led the firm’s investments in and currently also serves on the Board of Directors of Camp4 Therapeutics Corporation since March 2021, Fellow Health, Inc. since August 2022, Radionetics Oncology, Inc. since September 2021, Rarecyte, Inc. since December 2019, Scientist.com since November 2019, and TMRW Holdings, LLC since December 2019. Mr. Schwab previously served on the Board of Directors of… | SELL | 11,758 | $71.3K | +44.2% | +53.7% | |
| 9/11/2024 | SKYESkye Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | 5AM CO-INVESTORS II LP · 5AM Partners II, LLC · 5AM Partners VII, LLC · 5AM Ventures II LP · 5AM Ventures VII, L.P. · DIEKMAN JOHN D · PARMAR KUSH · ROCKLAGE SCOTT M10% owner | SELL | 36,504 | $240.9K | +42.5% | +60.0% | |
| 9/11/2024 | SKYESkye Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | 5AM CO-INVESTORS II LP · 5AM Partners II, LLC · 5AM Partners VII, LLC · 5AM Ventures II LP · 5AM Ventures VII, L.P. · DIEKMAN JOHN D · PARMAR KUSH · ROCKLAGE SCOTT M10% owner | SELL | 214,556 | $1.42M | +42.5% | +60.0% | |
| 9/11/2024 | SKYESkye Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | 5AM CO-INVESTORS II LP · 5AM Partners II, LLC · 5AM Partners VII, LLC · 5AM Ventures II LP · 5AM Ventures VII, L.P. · DIEKMAN JOHN D · PARMAR KUSH · ROCKLAGE SCOTT M10% owner | SELL | 1,440 | $9.5K | +42.5% | +60.0% | |
| 9/11/2024 | SKYESkye Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | Schwab Andrew J.10% owner and DirectorAndrew J. Schwab has served on our Board of Directors since the closing of our merger with Bird Rock Bio in August 2023 . Mr. Schwab is a Founding Partner and Managing Member of 5AM Venture Management, LLC, a venture capital firm focused on next generation life science investments founded in 2002. At 5AM, Mr. Schwab has led the firm’s investments in and currently also serves on the Board of Directors of Camp4 Therapeutics Corporation since March 2021, Fellow Health, Inc. since August 2022, Radionetics Oncology, Inc. since September 2021, Rarecyte, Inc. since December 2019, Scientist.com since November 2019, and TMRW Holdings, LLC since December 2019. Mr. Schwab previously served on the Board of Directors of… | SELL | 214,556 | $1.42M | +42.5% | +60.0% | |
| 9/11/2024 | SKYESkye Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | Schwab Andrew J.10% owner and DirectorAndrew J. Schwab has served on our Board of Directors since the closing of our merger with Bird Rock Bio in August 2023 . Mr. Schwab is a Founding Partner and Managing Member of 5AM Venture Management, LLC, a venture capital firm focused on next generation life science investments founded in 2002. At 5AM, Mr. Schwab has led the firm’s investments in and currently also serves on the Board of Directors of Camp4 Therapeutics Corporation since March 2021, Fellow Health, Inc. since August 2022, Radionetics Oncology, Inc. since September 2021, Rarecyte, Inc. since December 2019, Scientist.com since November 2019, and TMRW Holdings, LLC since December 2019. Mr. Schwab previously served on the Board of Directors of… | SELL | 36,504 | $240.9K | +42.5% | +60.0% | |
| 9/11/2024 | SKYESkye Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | Schwab Andrew J.10% owner and DirectorAndrew J. Schwab has served on our Board of Directors since the closing of our merger with Bird Rock Bio in August 2023 . Mr. Schwab is a Founding Partner and Managing Member of 5AM Venture Management, LLC, a venture capital firm focused on next generation life science investments founded in 2002. At 5AM, Mr. Schwab has led the firm’s investments in and currently also serves on the Board of Directors of Camp4 Therapeutics Corporation since March 2021, Fellow Health, Inc. since August 2022, Radionetics Oncology, Inc. since September 2021, Rarecyte, Inc. since December 2019, Scientist.com since November 2019, and TMRW Holdings, LLC since December 2019. Mr. Schwab previously served on the Board of Directors of… | SELL | 1,440 | $9.5K | +42.5% | +60.0% | |
| 3/13/2024 | SKYESkye Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | 5AM CO-INVESTORS II LP · 5AM Partners II, LLC · 5AM Partners VII, LLC · 5AM Ventures II LP · 5AM Ventures VII, L.P. · DIEKMAN JOHN D · PARMAR KUSH · ROCKLAGE SCOTT M10% owner | BUY | 450,000 | $4.50M | −3.03% | −39.8% | |
| 1/31/2024 | SKYESkye Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | 5AM CO-INVESTORS II LP · 5AM Partners II, LLC · 5AM Partners VII, LLC · 5AM Ventures II LP · 5AM Ventures VII, L.P. · DIEKMAN JOHN D · PARMAR KUSH · ROCKLAGE SCOTT M10% owner | BUY | 5,206,074 | $12.03M | +223.3% | +49.2% | |
| 8/29/2023 | SKYESkye Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | DHILLON PUNITChief Executive Officer | BUY | 881,000 | $17.6K | −61.3% | +104.9% | |
| 8/29/2023 | SKYESkye Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | DHILLON PUNITChief Executive Officer | BUY | 881,000 | $17.6K | −61.3% | +104.9% | |
| 8/7/2020 | SKYESkye Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | Emerald Health Sciences Inc.10% owner | SELL | 2,566,666 | $256.7K | +13.3% | −184.4% | |
| 8/7/2020 | SKYEEmerald Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | DHILLON PUNITCEO | BUY | 1,000,000 | $100.00B | −13.3% | +184.4% | |
| 8/7/2020 | SKYEEmerald Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | Emerald Health Sciences Inc.10% owner | SELL | 3,000,000 | $300.0K | +13.3% | −184.4% | |
| 8/7/2020 | SKYEEmerald Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | HEPPELL JAMES LDirector | BUY | 500,000 | $25.00B | −13.3% | +184.4% | |
| 8/7/2020 | SKYEEmerald Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | Emerald Health Sciences Inc.10% owner | SELL | 2,566,666 | $256.7K | +13.3% | −184.4% | |
| 2/16/2018 | SKYENemus Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | Emerald Health Sciences Inc.10% owner | BUY | 15,000,000 | — | −19.5% | −36.2% | |
| 4/10/2015 | SKYENemus Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | Ladin Brian D10% owner | SELL | 11,830 | $58.3K | +64.9% | +85.6% | |
| 4/8/2015 | SKYENemus Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | Ladin Brian D10% owner | SELL | 23,000 | $107.9K | +67.6% | +88.2% | |
| 4/8/2015 | SKYENemus Bioscience, Inc Skye Bioscience, Inc · Pharmaceutical PreparationsIndustryPharmaceutical PreparationsMkt cap (est.)$34.63MPrice$1.7652w high$38.0052w low$1.57 | Ladin Brian D10% owner | SELL | 15,800 | $75.7K | +67.6% | +88.2% |
Chart shows split-adjusted close for the last three years, or the selected date range. Triangles mark open-market Form 4 purchases and sales in that window.